^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

decitabine/ tetrahydrouridine (EPI01)

i
Other names: EPI01, EPI 01, NN7533, NN 7533, Eclipse, NDec
Company:
EpiDestiny, Novo Nordisk
Drug class:
DNA methylation inhibitor, Cytidine deaminase inhibitor
4ms
Enrollment open
|
decitabine/ tetrahydrouridine (EPI01)
7ms
New P1 trial
|
decitabine/ tetrahydrouridine (EPI01)
10ms
ASCENT1: Research Study Investigating How Well NDec Works in People With Sickle Cell Disease (clinicaltrials.gov)
P2, N=84, Recruiting, Novo Nordisk A/S | Trial primary completion date: Nov 2023 --> Oct 2024
Trial primary completion date
|
hydroxyurea • decitabine/ tetrahydrouridine (EPI01)